Supernus Pharmaceuticals Inc

The asset is in a Stage 2 advancing phase with a recent momentum breakout signaling fresh demand. Medium-term bias remains bullish and aligned with the uptrend, but price is currently extended above rising EMAs and overbought. Short-term execution readiness is limited, so entry should be deferred. Focus on pullbacks into the rising EMAs and prior resistance zone near the breakout level for optimal execution while the long-term uptrend remains intact.

• ↑39% YoY revenue growth to $207.7M in Q1 2026
• ↑Ongoing trials for SPN-820 & SPN-817 with FDA submission due
• ↓Q1 operating loss of $8.3M highlights profitability struggles